Cite
HARVARD Citation
Ip, H. et al. (n.d.). 193PPrognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG). Annals of oncology. p. . [Online].